Ganfort PF

Per mL Timolol 5 mg, bimatoprost 0.3 mg

Reduction of IOP in open-angle glaucoma or ocular HTN insufficiently responsive to topical β-blockers or prostaglandin analogues.

1 drop in the affected eye(s) once daily in the morning or evening at the same time each day.

Hypersensitivity. Bronchial asthma, severe COPD, sinus bradycardia, 2nd-or 3rd-degree AV block, overt cardiac failure, cardiogenic shock. History of bronchial asthma; sinus bradycardia, sick sinus syndrome, SA nodal block.

Active intraocular inflammation (eg, uveitis). Aphakic patients, pseudophakic patients w/ torn posterior lens capsule or w/ known risk factors for macular edema (eg, intraocular surgery, retinal vein occlusions, ocular inflammatory disease & diabetic retinopathy). Potential permanent increased brown iris pigmentation, & hair growth in skin areas. Monitor for IOP changes. Patients w/ inflammatory ocular conditions, neovascular glaucoma, inflammatory glaucoma, angle-closure glaucoma, congenital or narrow-angle glaucoma. Preexisting or history of CV disease (eg, CHD, Prinzmetal's angina & cardiac failure) & hypotension. 1st degree heart block. Severe peripheral circulatory disturbance/disorders (ie, Raynaud's phenomenon). Mild or moderate COPD. History of atopy or severe anaphylactic reactions. Diabetics (especially those w/ labile diabetes). May mask signs of hyperthyroidism & hypoglycemia. Corneal disease. Choroidal detachment. Concomitant use w/ other β-blocking agents & surgical anesth. Remove contact lenses prior to administration & reinsert at least 15 min after instillation. May have negligible influence on the ability to drive or use machines. Renal or hepatic impairment. Pregnancy & lactation. Childn or adolescent.

Conjunctival hyperemia, growth of eyelashes, superficial punctate keratitis, eye pruritus, foreign body sensation in the eyes, eye dryness, eyelid erythema, photophobia. Eye irritation, increased lacrimation, conjunctival irritation; headache; skin (periocular) hyperpigmentation. Eyelid pruritus, abnormal sensation in eye, eyelash discoloration, eyelid edema, asthenopia, fatigue.

Potential additive effects w/ systemic β-adrenergic blocking agents. Hypotension/bradycardia w/ Ca channel blockers (oral), anti-arrhythmics (including amiodarone, digitalis glycosides, parasympathomimetics, guanethidine & other antihypertensives. Mydriasis w/ adrenaline. Potentiated systemic β-blockade w/ CYP2D6 inhibitors.

Antiglaucoma Preparations

S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

S